AstraZeneca, Daiichi Sankyo and Summit Plan Datroway–Ivonescimab Clinical Programme Across Multiple Cancers

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

TOKYO--(BUSINESS WIRE)--Oct 2, 2026-

Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone

Plus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Trop-2-directed antibody-drug ...

AstraZeneca, Daiichi Sankyo and Summit plan Datroway–ivonescimab clinical programme across multiple cancers

The collaboration is set to begin with a Phase III trial in first-line triple-negative breast cancer, with the partners sharing trial costs while retaining rights to their respective medicines. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca and Daiichi Sankyo have entered into a … Read the full press release →

Summit Therapeutics Inc. plans Datroway Phase III trial

A planned Phase III breast cancer study would test ivonescimab alongside Datroway as Summit Therapeutics Inc. (NASDAQ: SMMT) joined a three-company clinical collaboration on Friday. The agreement follows AstraZeneca's Sept. 28 announcement of a US$2 billion equity investment in Summit that it said would partly support combination studies. AstraZeneca PLC (LON: AZN) (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) jointly develop and commercialize Datr…